Fintel reports that on November 13, 2024, JMP Securities downgraded their outlook for Syros Pharmaceuticals (NasdaqGS:SYRS) ...

JMP Securities analyst Jason Butler downgraded Syros Pharmaceuticals (SYRS) to Market Perform from Outperform without a price target The firm cites the “disappointing results” from the Phase 3 ...

TD Cowen analyst Phil Nadeau downgraded Syros Pharmaceuticals (SYRS) to Hold from Buy after the company announced that the SELECT-MDS-1 Phase 3 ...

Renamed newcomer will be positioned between the Sonet and Seltos and go on-sale in early 2025 in India with South African market availability unknown at present.

Shares of Syros Pharmaceuticals collapsed in premarket trading Wednesday after the biopharmaceutical company's lead asset, tamibarotene, failed in a late-stage study in a rare blood cancer.

Kia announces the Syros SUV, the first under its 2.0 strategy in India, blending modern design with advanced technology and ...

With the Phase III failure, Syros will discontinue the study of tamibarotene for myelodysplastic syndrome and will default on ...

Syros’. The vehicle has been designed to marry Kia's contemporary design language with mythical creativity, providing a ...

Kia Motors has officially announced its upcoming compact SUV, the Syros, anticipated to hit the global market in the coming weeks with a full launch likely early next year. This model, previously ...

The new Kia Syros will soon be unveiled in India. And judging by a local trademark filing, this small boxy SUV could be on ...

After the launch of EV9 flagship electric SUV and Carnival premium MPV, Kia Syros will be the first SUV to launch under 2.0 ...

Kia India has introduced its latest SUV, the SYROS, in the Kia 2.0 lineup, emphasizing a high-tech, bold design. This new ...